Ultrasound imaging of thyroid may identify cancers among low-risk patients; decrease rate of unnecessary thyroid biopsies.
Ultrasound imaging of the thyroid may help identify low-risk thyroid cancer patients, according to a study published in JAMA.
Researchers from the University of California, San Francisco, undertook a study to quantify the risk of thyroid cancer associated with thyroid nodules, based on ultrasound imaging characteristics.
The retrospective, case-controlled study assessed 8,806 patients who underwent 11,618 thyroid ultrasound examinations from January 2000 through March 2005. A total of 105 patients were subsequently diagnosed with thyroid cancer.
It was found that thyroid nodules were common among patients who had thyroid cancer (96.9 percent) and also among those who did not (56.4 percent).
The researchers noted that there were three ultrasound nodule characteristics that were only associated with the risk of thyroid cancer:
· Microcalcifications
· Size greater than 2 cm
· Entirely solid composition
It was determined that most cases of thyroid cancer could be detected if biopsies were performed based on using one characteristic as indication for the procedure. Two characteristics as basis for biopsy would bring the sensitivity and false-positive rates lower with a higher positive likelihood ratio.
These results showed the rate of unnecessary biopsies could be reduced by 90 percent while maintaining a low risk of cancer if there were a more stringent approach for performing biopsies, researchers said.
"Adoption of uniform standards for the interpretation of thyroid sonograms would be a first step toward standardizing the diagnosis and treatment of thyroid cancer and limiting unnecessary diagnostic testing and treatment," the study concluded.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.